Form 4 for BRTX BioRestorative Therapies, Inc.
Accepted 2022-03-22 00:00:00 ET · period of report 2022-03-18 · accession 0001567619-22-007347 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-22 | 2022-03-18 | BRTX | ALSTODT LANCE | Pres, CEO, COB, Dir | A - Grant | — | +12.4K | 175.5K | +8% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-18 | A | A | 12,438 | — | 175,521 | D | — | — | (F1) Shares received pursuant to a restricted stock unit grant. Vests in twelve nearly equal monthly installments beginning April 18, 2022. (F2) Includes 110,264 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on April 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. |